Summit Therapeutics (SMMT) Return on Capital Employed (2020 - 2024)
Summit Therapeutics' (SMMT) quarterly Return on Capital Employed came in at 52.87% in Q4 2024, up 26748.0% YoY from N/an in Q1 2024, and up 2.29% on a QoQ basis from 54.11% in Q3 2024.
Summit Therapeutics (SMMT) Return on Capital Employed (2020 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 5 years of Return on Capital Employed data on file, last reported at 52.87% in Q4 2024.
- Quarterly Return on Capital Employed rose 26748.0% year-over-year to 52.87% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 52.87% (up 26748.0% YoY) and the FY2024 annual result came in at 81.43%, up 6613.0% from the prior year.
- Return on Capital Employed advanced to 52.87% in Q4 2024, from 54.11% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.43% in Q4 2022 to a low of 519.99% in Q3 2023.
- A 5-year average of 132.71% and a median of 90.34% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 44848 bps — and 2024, when it surged 46589 bps.
- Tracing SMMT's Return on Capital Employed over 5 years: stood at 108.08% in 2020, then climbed by 16 bps to 90.34% in 2021, then jumped by 78 bps to 19.43% in 2022, then tumbled by 1549 bps to 320.35% in 2023, then surged by 83 bps to 52.87% in 2024.
- The last three Return on Capital Employed figures came in at 52.87% (Q4 2024), 54.11% (Q3 2024), and 133.2% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -52.87% |
| Sep 30, 2024 | -54.11% |
| Jun 30, 2024 | -133.20% |
| Mar 31, 2024 | -69.03% |
| Dec 31, 2023 | -320.35% |
| Sep 30, 2023 | -519.99% |
| Jun 30, 2023 | -252.00% |
| Mar 31, 2023 | -132.80% |
| Dec 31, 2022 | -19.43% |
| Sep 30, 2022 | -71.51% |
| Jun 30, 2022 | -88.41% |
| Mar 31, 2022 | -99.16% |
| Dec 31, 2021 | -90.34% |
| Sep 30, 2021 | -62.72% |
| Jun 30, 2021 | -57.02% |
| Mar 31, 2021 | -125.07% |
| Dec 31, 2020 | -108.08% |